Huang Yajing, Wei Shumei, Hu Kaimin, Xiang Xueping
Department of Pathology, the Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
Department of Breast Surgery and Oncology, the Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
Front Oncol. 2025 May 29;15:1562539. doi: 10.3389/fonc.2025.1562539. eCollection 2025.
Breast cancer remains one of the leading causes of cancer-related morbidity and mortality among women worldwide. Recent advancements in our understanding of DNA damage repair (DDR) mechanisms have shed light on their specific role in the pathogenesis, progression, treatment resistance, and prognosis of breast cancer. In this study, we conducted a bibliometric study to map the global trends in DDR-related breast cancer research.
A search of publications on DDR in breast cancer from 1990 to 2024 was conducted using the Web of Science Core Collection. A comprehensive bibliometric analysis of the data was performed using CiteSpace, VOSviewer, and Bibliometrix. Additionally, for clinical trial data, the databases ClinicalTrials.gov (https://www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (https://trialsearch.who.int) were queried.
The results revealed a continuous and steady growth in the number of articles published in this area over the past three decades and showed that the USA had produced the highest number of publications in this field, while Harvard University had published the largest number of articles. Jonkers, Jos was found to be the most published author, with 39 documents. Analysis of the journals showed that ranked as the most published journal, while was the most cited. Combined with the keyword co-occurrence analysis and co-citation analysis, it emerged that "Targeting the DNA repair defect as a therapeutic strategy", published in (IF = 64.8) in 2005, had accumulated 529 local citations, indicating that research topics have focused on treatment regimens. For clinical trials, 124 studies were initially sourced-108 from ClinicalTrials.gov and 16 from ICTRP. After repetitive and correlation-based screening, 43 trials specifically addressing 13 different DDR-related drugs in breast cancer were included.
Overall, this study provides valuable insights into the current research achievements, latest advancements, and emerging global trends in DNA damage repair-related breast cancer research. With sustained clinical focus, more high-quality investigations combining DDR inhibitors with other treatment modalities are needed.
乳腺癌仍然是全球女性癌症相关发病和死亡的主要原因之一。我们对DNA损伤修复(DDR)机制的理解最近取得的进展,揭示了它们在乳腺癌的发病机制、进展、治疗耐药性和预后中的特定作用。在本研究中,我们进行了一项文献计量学研究,以描绘DDR相关乳腺癌研究的全球趋势。
使用科学网核心合集对1990年至2024年关于乳腺癌DDR的出版物进行检索。使用CiteSpace、VOSviewer和Bibliometrix对数据进行全面的文献计量分析。此外,对于临床试验数据,查询了ClinicalTrials.gov数据库(https://www.clinicaltrials.gov)和世界卫生组织国际临床试验注册平台(ICTRP)(https://trialsearch.who.int)。
结果显示,在过去三十年中,该领域发表的文章数量持续稳定增长,表明美国在该领域发表的文章数量最多,而哈佛大学发表的文章数量最多。发现Jonkers, Jos是发表文章最多的作者,有39篇文献。对期刊的分析表明, 是发表文章最多的期刊,而 是被引用最多的期刊。结合关键词共现分析和共被引分析,发现2005年发表在 (IF = 64.8)上的“将DNA修复缺陷作为治疗策略”积累了529次本地引用,表明研究主题集中在治疗方案上。对于临床试验,最初获取了124项研究——108项来自ClinicalTrials.gov,16项来自ICTRP。经过基于重复和相关性的筛选,纳入了43项专门针对乳腺癌中13种不同DDR相关药物的试验。
总体而言,本研究为DNA损伤修复相关乳腺癌研究的当前研究成果、最新进展和新兴全球趋势提供了有价值的见解。随着临床持续关注,需要更多将DDR抑制剂与其他治疗方式相结合的高质量研究。